QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
QQQ   306.18 (-1.78%)
AAPL   154.50 (+2.44%)
MSFT   258.35 (-2.36%)
META   186.53 (-1.19%)
GOOGL   104.78 (-2.75%)
AMZN   103.39 (-8.43%)
TSLA   189.98 (+0.91%)
NVDA   211.00 (-2.81%)
NIO   11.19 (-6.44%)
BABA   106.33 (-3.11%)
AMD   86.09 (-2.51%)
T   19.83 (-2.22%)
F   13.23 (-7.61%)
MU   62.41 (-1.20%)
CGC   2.92 (-7.01%)
GE   81.96 (-2.36%)
DIS   110.71 (-2.21%)
AMC   6.08 (+0.00%)
PFE   44.06 (-0.63%)
PYPL   85.52 (-1.66%)
NFLX   365.90 (-0.27%)
NYSE:TEVA

Teva Pharmaceutical Industries - TEVA Stock Forecast, Price & News

$10.76
+0.05 (+0.47%)
(As of 02/3/2023 12:00 AM ET)
Add
Compare
Today's Range
$10.61
$10.80
50-Day Range
$8.32
$11.37
52-Week Range
$6.78
$11.44
Volume
7.04 million shs
Average Volume
10.28 million shs
Market Capitalization
$11.95 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Teva Pharmaceutical Industries MarketRank™ Forecast

Analyst Rating
Hold
2.00 Rating Score
Upside/​Downside
0.9% Downside
$10.67 Price Target
Short Interest
Healthy
2.25% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.04mentions of Teva Pharmaceutical Industries in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
-0.83%
From $2.40 to $2.38 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.35 out of 5 stars

Medical Sector

957th out of 1,029 stocks

Pharmaceutical Preparations Industry

463rd out of 501 stocks

TEVA stock logo

About Teva Pharmaceutical Industries (NYSE:TEVA) Stock

Teva Pharmaceutical Industries Ltd. engages in the development and production of medicines. Its products include medicines for cardiovascular diseases, pain relievers, obesity, cancer and supportive care, infectious diseases and human immunodeficiency viruses, and colds and coughs. The firm operates through following geographical segments: North America, Europe and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.

Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Stock News Headlines

A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
A gold storm is coming…
“We are in the early stages of a mania – the calm before the storm.”...
See More Headlines
Receive TEVA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Teva Pharmaceutical Industries and its competitors with MarketBeat's FREE daily newsletter.

TEVA Company Calendar

Last Earnings
10/27/2021
Today
2/03/2023
Next Earnings (Confirmed)
2/08/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Employees
37,537
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$13.00
Low Stock Price Forecast
$7.00
Forecasted Upside/Downside
-0.9%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
9 Analysts

Profitability

Net Income
$417 million
Pretax Margin
-14.14%

Debt

Sales & Book Value

Annual Sales
$15.88 billion
Cash Flow
$3.74 per share
Book Value
$10.19 per share

Miscellaneous

Outstanding Shares
1,110,560,000
Free Float
1,101,458,000
Market Cap
$11.95 billion
Optionable
Optionable
Beta
1.22

Key Executives

  • Richard Francis
    President, Chief Executive Officer & Director
  • Eric DrapéEric Drapé
    Executive Vice President-Global Operations
  • Eli Kalif
    Chief Financial Officer & Executive Vice President
  • Eric A. Hughes
    Chief Medical Officer, Executive VP-Global R&D
  • Kathleen Veit
    Senior VP-Global Compliance & Ethics Officer













TEVA Stock - Frequently Asked Questions

Should I buy or sell Teva Pharmaceutical Industries stock right now?

9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Teva Pharmaceutical Industries in the last year. There are currently 3 sell ratings, 3 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" TEVA shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in TEVA, but not buy additional shares or sell existing shares.
View TEVA analyst ratings
or view top-rated stocks.

What is Teva Pharmaceutical Industries' stock price forecast for 2023?

9 Wall Street analysts have issued twelve-month price objectives for Teva Pharmaceutical Industries' stock. Their TEVA share price forecasts range from $7.00 to $13.00. On average, they predict the company's stock price to reach $10.67 in the next year. This suggests that the stock has a possible downside of 0.6%.
View analysts price targets for TEVA
or view top-rated stocks among Wall Street analysts.

How have TEVA shares performed in 2023?

Teva Pharmaceutical Industries' stock was trading at $9.12 at the beginning of the year. Since then, TEVA shares have increased by 17.7% and is now trading at $10.73.
View the best growth stocks for 2023 here
.

Are investors shorting Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries saw a decrease in short interest in the month of January. As of January 15th, there was short interest totaling 25,020,000 shares, a decrease of 20.5% from the December 31st total of 31,470,000 shares. Based on an average trading volume of 9,750,000 shares, the days-to-cover ratio is currently 2.6 days.
View Teva Pharmaceutical Industries' Short Interest
.

When is Teva Pharmaceutical Industries' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 8th 2023.
View our TEVA earnings forecast
.

How can I listen to Teva Pharmaceutical Industries' earnings call?

Teva Pharmaceutical Industries will be holding an earnings conference call on Wednesday, February 8th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Teva Pharmaceutical Industries' earnings last quarter?

Teva Pharmaceutical Industries Limited (NYSE:TEVA) announced its earnings results on Wednesday, October, 27th. The company reported $0.59 earnings per share for the quarter, missing analysts' consensus estimates of $0.65 by $0.06. The business had revenue of $3.89 billion for the quarter, compared to the consensus estimate of $4.05 billion. Teva Pharmaceutical Industries had a negative net margin of 8.52% and a positive trailing twelve-month return on equity of 26.97%. Teva Pharmaceutical Industries's revenue for the quarter was down 2.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.56 earnings per share.

What guidance has Teva Pharmaceutical Industries issued on next quarter's earnings?

Teva Pharmaceutical Industries issued an update on its FY 2022 earnings guidance on Thursday, November, 10th. The company provided earnings per share (EPS) guidance of $2.40-$2.60 for the period, compared to the consensus EPS estimate of $2.50. The company issued revenue guidance of $14.80 billion-$15.40 billion, compared to the consensus revenue estimate of $15.46 billion.

What is Kåre Schultz's approval rating as Teva Pharmaceutical Industries' CEO?

158 employees have rated Teva Pharmaceutical Industries Chief Executive Officer Kåre Schultz on Glassdoor.com. Kåre Schultz has an approval rating of 90% among the company's employees.

What other stocks do shareholders of Teva Pharmaceutical Industries own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Teva Pharmaceutical Industries investors own include General Electric (GE), AT&T (T), NVIDIA (NVDA), Alibaba Group (BABA), Intel (INTC), Bank of America (BAC), Micron Technology (MU), Gilead Sciences (GILD), Johnson & Johnson (JNJ) and Cisco Systems (CSCO).

What is Teva Pharmaceutical Industries' stock symbol?

Teva Pharmaceutical Industries trades on the New York Stock Exchange (NYSE) under the ticker symbol "TEVA."

Who are Teva Pharmaceutical Industries' major shareholders?

Teva Pharmaceutical Industries' stock is owned by a number of institutional and retail investors. Top institutional investors include Migdal Insurance & Financial Holdings Ltd. (1.94%), Harel Insurance Investments & Financial Services Ltd. (1.36%), Sumitomo Mitsui Trust Holdings Inc. (0.24%), AustralianSuper Pty Ltd (0.22%), Simplex Trading LLC (0.00%) and Private Management Group Inc. (0.12%). Insiders that own company stock include Brendan P O'grady, David Matthew Stark, Deborah A Griffin, Eli Shani, Eliyahu Sharon Kalif, Eric Drape, Hafrun Fridriksdottir, Mark Sabag, Pharmaceutical Co Ltd Takeda, Richard Daniell, Rosemary A Crane and Sven Dethlefs.
View institutional ownership trends
.

How do I buy shares of Teva Pharmaceutical Industries?

Shares of TEVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Teva Pharmaceutical Industries' stock price today?

One share of TEVA stock can currently be purchased for approximately $10.73.

How much money does Teva Pharmaceutical Industries make?

Teva Pharmaceutical Industries (NYSE:TEVA) has a market capitalization of $11.92 billion and generates $15.88 billion in revenue each year. The company earns $417 million in net income (profit) each year or ($1.16) on an earnings per share basis.

How many employees does Teva Pharmaceutical Industries have?

The company employs 37,537 workers across the globe.

How can I contact Teva Pharmaceutical Industries?

Teva Pharmaceutical Industries' mailing address is 5 BAZEL ST P O B 3190, PETACH TIKVA L3, 49131. The official website for the company is www.tevapharm.com. The company can be reached via phone at (723) 914-8213, via email at kevin.mannix@tevapharm.com, or via fax at 972-3923-4050.

This page (NYSE:TEVA) was last updated on 2/3/2023 by MarketBeat.com Staff